Lang Berenice M, Balermpas Panagiotis, Bauer Andrea, Blum Andreas, Dirschka Thomas, Follmann Markus, Frank Jorge, Frerich Bernhard, Fritz Klaus, Hauschild Axel, Heindl Ludwig M, Howaldt Hans-Peter, Ihrler Stephan, Kakkassery Vinodh, Klumpp Bernhard, Krause-Bergmann Albrecht, Löser Christoph, Meissner Markus, Sachse Michael M, Schlaak Max, Schön Michael P, Tischendorf Lutz, Tronnier Michael, Vordermark Dirk, Welzel Julia, Weichenthal Michael, Wiegand Susanne, Kaufmann Roland, Grabbe Stephan
Department of Dermatology, Mainz University Medical Center, Mainz, Germany.
Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland.
J Dtsch Dermatol Ges. 2024 Dec;22(12):1697-1714. doi: 10.1111/ddg.15566. Epub 2024 Nov 25.
Basal cell carcinoma is the most common malignant tumor in the fair-skinned population and its incidence continues to rise. An update of the S2k guideline with the participation of all specialist societies familiar with the clinical picture and previous literature research is of great importance for the quality of care for affected patients. In addition to epidemiology, diagnostics and histology are discussed. After risk stratification, therapy is divided into topical, systemic and radiation therapy. Surgical removal remains the treatment of first choice in most cases. The approval of anti-PD1 inhibitors for locally advanced and metastatic tumors has opened up a new option in second-line therapy (after hedgehog inhibitors).
基底细胞癌是白种人群中最常见的恶性肿瘤，其发病率持续上升。由熟悉临床表现和既往文献研究的所有专业学会参与更新的S2k指南，对提高受影响患者的护理质量至关重要。除了流行病学，还讨论了诊断和组织学。在进行风险分层后，治疗分为局部治疗、全身治疗和放射治疗。在大多数情况下，手术切除仍然是首选的治疗方法。抗PD1抑制剂获批用于局部晚期和转移性肿瘤，为二线治疗（在使用刺猬抑制剂之后）开辟了新的选择。
